Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety ProfilePRNewsWire • 10/04/23
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC SymposiumPRNewsWire • 09/18/23
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid TumorsPRNewsWire • 09/05/23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial ResultsPRNewsWire • 08/10/23
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's WhyZacks Investment Research • 07/21/23
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 06/07/23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial ResultsPRNewsWire • 05/11/23
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023PRNewsWire • 04/18/23
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)PRNewsWire • 03/23/23
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsPRNewsWire • 03/16/23
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023PRNewsWire • 03/14/23
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 01/02/23
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520PRNewsWire • 12/13/22
MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 12/11/22